ATE279194T1 - Behandlung von rückenmarkverletzungenbedingter impotenz - Google Patents

Behandlung von rückenmarkverletzungenbedingter impotenz

Info

Publication number
ATE279194T1
ATE279194T1 AT99301085T AT99301085T ATE279194T1 AT E279194 T1 ATE279194 T1 AT E279194T1 AT 99301085 T AT99301085 T AT 99301085T AT 99301085 T AT99301085 T AT 99301085T AT E279194 T1 ATE279194 T1 AT E279194T1
Authority
AT
Austria
Prior art keywords
spinal cord
cord injury
impotency
treatment
male
Prior art date
Application number
AT99301085T
Other languages
English (en)
Inventor
Murray Craig Maytom
Ian Howard Osterloh
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Application granted granted Critical
Publication of ATE279194T1 publication Critical patent/ATE279194T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrotherapy Devices (AREA)
AT99301085T 1998-02-23 1999-02-15 Behandlung von rückenmarkverletzungenbedingter impotenz ATE279194T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7558098P 1998-02-23 1998-02-23

Publications (1)

Publication Number Publication Date
ATE279194T1 true ATE279194T1 (de) 2004-10-15

Family

ID=22126701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99301085T ATE279194T1 (de) 1998-02-23 1999-02-15 Behandlung von rückenmarkverletzungenbedingter impotenz

Country Status (17)

Country Link
US (1) US20060040935A1 (de)
EP (1) EP0951908B1 (de)
JP (1) JPH11315025A (de)
KR (1) KR19990072798A (de)
AT (1) ATE279194T1 (de)
AU (1) AU755402B2 (de)
CA (1) CA2262268C (de)
DE (1) DE69921008T2 (de)
DK (1) DK0951908T3 (de)
ES (1) ES2226281T3 (de)
HU (1) HUP9900438A3 (de)
IL (1) IL128532A0 (de)
MY (1) MY133446A (de)
NZ (1) NZ334333A (de)
PT (1) PT951908E (de)
TW (1) TW542719B (de)
ZA (1) ZA991393B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
AU4663100A (en) 1999-04-30 2000-11-17 Lilly Icos Llc Treatment of female arousal disorder
KR20020062770A (ko) 1999-12-24 2002-07-29 바이엘 악티엔게젤샤프트 이미다조 1,3,5 트리아지논 및 그의 용도
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
KR100393160B1 (ko) * 2001-06-14 2003-07-31 한국과학기술연구원 신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
WO2002102385A1 (en) * 2001-06-14 2002-12-27 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
JP2007537247A (ja) 2004-05-11 2007-12-20 エモーショナル ブレイン ビー．ブイ． 女性性的機能不全の治療における薬学的製剤およびその使用方法
EP1790343A1 (de) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
EP1925307A1 (de) * 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
WO2008142396A1 (en) * 2007-05-18 2008-11-27 Anthony Denis Maher Methods of assessing male fertility using a uridine marker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
CA2262268A1 (en) 1999-08-23
AU755402B2 (en) 2002-12-12
MY133446A (en) 2007-11-30
DE69921008T2 (de) 2006-02-02
HUP9900438A2 (hu) 2000-03-28
EP0951908B1 (de) 2004-10-13
PT951908E (pt) 2005-01-31
IL128532A0 (en) 2000-01-31
DE69921008D1 (de) 2004-11-18
NZ334333A (en) 2000-11-24
AU1839099A (en) 1999-09-09
ES2226281T3 (es) 2005-03-16
HU9900438D0 (en) 1999-04-28
KR19990072798A (ko) 1999-09-27
TW542719B (en) 2003-07-21
ZA991393B (en) 2000-08-22
CA2262268C (en) 2003-07-29
US20060040935A1 (en) 2006-02-23
DK0951908T3 (da) 2004-12-27
HUP9900438A3 (en) 2002-01-28
EP0951908A3 (de) 2000-08-16
JPH11315025A (ja) 1999-11-16
EP0951908A2 (de) 1999-10-27

Similar Documents

Publication Publication Date Title
ATE279194T1 (de) Behandlung von rückenmarkverletzungenbedingter impotenz
AR016993A1 (es) Formulaciones intranasales para tratar trastornos sexuales
ATE233091T1 (de) Verwendung von histamine-2 agonisten zur behandlung sexueller funktionsstörungen
DE602004029369D1 (de) Halbfeste mukoadhäsive formulierungen
ATE245650T1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
BR9911060A (pt) Composições compreendendo mono- ou dinitrato orgânico para tratar impotência
EP1108426A3 (de) Anwendung von Prostaglandinagonisten zur Behandlung der Erektionstörungen und Impotenz
ID24184A (id) Obat untuk perawatan disfungsi ereksi
PT1109814E (pt) 5-heterociclil pirazol¬4,3-d|pirimidina-7-onas para o tratamento da disfuncao erectil masculina
DK1150698T3 (da) Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
HUP0400528A2 (hu) Neuropeptidáz Y inhibitor alkalmazása férfiak szexuális funkciózavarának kezelésére alkalmas gyógyszerkészítmény előállítására
MD1979F1 (en) Method of secondary cataract treatment
GB2277265A (en) Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema
ATE367823T1 (de) E-selectin zur behandlung oder vorbeugung von schlaganfall
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
WO1996036339A3 (en) Use of dihydrotestosterone compounds for treating male sexual dysfunction
WO2005051368A3 (en) Phosphodiesterase v inhibitor formulations
ATE144141T1 (de) Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz
RU93058537A (ru) Применение атипамезола для лечения мужской сексуальной импотенции
ECSP993027A (es) Formulaciones intranasales para trastornos sexuales
PT1355650E (pt) Combinacao de ingredientes activos contendo alfuzosina e apomorfina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0951908

Country of ref document: EP

REN Ceased due to non-payment of the annual fee